Michael Becker to Humans
This is a "connection" page, showing publications Michael Becker has written about Humans.
Connection Strength
0.758
-
Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis Rheumatol. 2017 01; 69(1):203-212.
Score: 0.019
-
Summary of the 2015 Purine and Pyrimidine Society/Purine Metabolic Patients Association H. Anne Simmonds Memorial Lecture. Nucleosides Nucleotides Nucleic Acids. 2016 Dec; 35(10-12):502-506.
Score: 0.019
-
Myocardial deformation by strain echocardiography identifies patients with acute coronary syndrome and non-diagnostic ECG presenting in a chest pain unit: a prospective study of diagnostic accuracy. Clin Res Cardiol. 2016 Mar; 105(3):248-56.
Score: 0.017
-
An open-label, 6-month study of allopurinol safety in gout: The LASSO study. Semin Arthritis Rheum. 2015 Oct; 45(2):174-83.
Score: 0.017
-
Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 2015; 31 Suppl 2:9-14.
Score: 0.016
-
Detection of coronary artery disease in postmenopausal women: the significance of integrated stress imaging tests in a 4-year prognostic study. Clin Res Cardiol. 2015 Mar; 104(3):258-71.
Score: 0.016
-
Urate transporters: transforming the face of hyperuricemia and gout. J Rheumatol. 2014 Oct; 41(10):1910-2.
Score: 0.016
-
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014 Mar 04; 16(2):R60.
Score: 0.015
-
Long-term management of gout: nonpharmacologic and pharmacologic therapies. Rheum Dis Clin North Am. 2014 May; 40(2):357-74.
Score: 0.015
-
The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation. Leuk Res. 2013 Sep; 37(9):1052-6.
Score: 0.015
-
Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab. 2013 Nov; 15(11):1049-55.
Score: 0.015
-
Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013 Sep 01; 72(9):1469-74.
Score: 0.014
-
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011 Dec; 30(12):1011-7.
Score: 0.013
-
Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011; 14(1):10-5.
Score: 0.012
-
What do I need to know about gout? J Fam Pract. 2010 Jun; 59(6 Suppl):S1-8.
Score: 0.012
-
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.
Score: 0.012
-
Trade-off in object versus spatial visualization abilities: restriction in the development of visual-processing resources. Psychon Bull Rev. 2010 Feb; 17(1):29-35.
Score: 0.012
-
Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009 May; 36(5):1041-8.
Score: 0.011
-
Update on emerging urate-lowering therapies. Curr Opin Rheumatol. 2009 Mar; 21(2):143-9.
Score: 0.011
-
PP07: new approaches, new knowledge, new challenges in human purine and pyrimidine metabolism. Nucleosides Nucleotides Nucleic Acids. 2008 Jun; 27(6):547-53.
Score: 0.010
-
In memoriam: J. Edwin Seegmiller, M.D. (1920-2006). Nucleosides Nucleotides Nucleic Acids. 2008 Jun; 27(6):554-6.
Score: 0.010
-
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008 Jun; 27(6):585-91.
Score: 0.010
-
Survival and quality of life in patients with cardiac resynchronization therapy for severe heart failure and in heart transplant recipients within a contemporary heart failure management program. J Heart Lung Transplant. 2008 Jul; 27(7):746-52.
Score: 0.010
-
We can make gout management more successful now. Curr Opin Rheumatol. 2008 Mar; 20(2):167-72.
Score: 0.010
-
Real-time pulmonary graphic monitoring. Clin Perinatol. 2007 Mar; 34(1):1-17, v.
Score: 0.009
-
Crystal-induced arthropathies: recent investigative advances. Curr Opin Rheumatol. 2006 May; 18(3):249-55.
Score: 0.009
-
Hyperuricemia and associated diseases. Rheum Dis Clin North Am. 2006 May; 32(2):275-93, v-vi.
Score: 0.009
-
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006; 8 Suppl 1:S4.
Score: 0.009
-
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 Dec 08; 353(23):2450-61.
Score: 0.009
-
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005 Mar; 52(3):916-23.
Score: 0.008
-
Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1111-6.
Score: 0.008
-
Sex on the internet: furthering our understanding of men with online sexual problems. Psychol Addict Behav. 2004 Sep; 18(3):223-30.
Score: 0.008
-
Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol. 2004 Aug; 31(8):1575-81.
Score: 0.008
-
Changing patterns of otitis media in the Waikato region during the COVID-19 pandemic. J Prim Health Care. 2023 09; 15(3):224-229.
Score: 0.007
-
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. Arthritis Rheumatol. 2022 09; 74(9):1593-1601.
Score: 0.007
-
Rheumatoid hyperviscosity syndrome: reversibility of microvascular abnormalities after treatment. Am J Ophthalmol. 2002 Jul; 134(1):130-2.
Score: 0.007
-
Parkinson's Disease Medication Administration During a Care Transition: The Impact of Interprofessional Team Simulation on Student Competency, Comfort, and Knowledge. Nurs Educ Perspect. 2022 May-Jun 01; 43(3):164-170.
Score: 0.007
-
Modes of neonatal and pediatric ventilation. Air Med J. 2001 Jan-Feb; 20(1):12-3.
Score: 0.006
-
Phosphoribosylpyrophosphate synthetase and the regulation of phosphoribosylpyrophosphate production in human cells. Prog Nucleic Acid Res Mol Biol. 2001; 69:115-48.
Score: 0.006
-
A phase II clinical trial of lenalidomide intensification in patients with serologic/asymptomatic progression of multiple myeloma while on lenalidomide maintenance: a tri-state transplant consortium study. Leuk Lymphoma. 2020 02; 61(2):488-490.
Score: 0.006
-
Cell type-specific differential expression of human PRPP synthetase (PRPS) genes. Adv Exp Med Biol. 2000; 486:5-10.
Score: 0.006
-
Speckle Tracking Echocardiography and All-Cause and Cardiovascular Mortality Risk in Chronic Kidney Disease Patients. Kidney Blood Press Res. 2019; 44(4):690-703.
Score: 0.006
-
Electronic Health Record Mortality Prediction Model for Targeted Palliative Care Among Hospitalized Medical Patients: a Pilot Quasi-experimental Study. J Gen Intern Med. 2019 09; 34(9):1841-1847.
Score: 0.006
-
Accelerated transcription of PRPS1 in X-linked overactivity of normal human phosphoribosylpyrophosphate synthetase. J Biol Chem. 1999 Mar 12; 274(11):7482-8.
Score: 0.005
-
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Arthritis Rheumatol. 2019 01; 71(1):143-153.
Score: 0.005
-
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Res Ther. 2018 05 30; 20(1):99.
Score: 0.005
-
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018 Mar 29; 378(13):1200-1210.
Score: 0.005
-
Use of two-dimensional speckle tracking echocardiography to predict cardiac events: Comparison of patients with acute myocardial infarction and chronic coronary artery disease. Clin Cardiol. 2018 Jan; 41(1):111-118.
Score: 0.005
-
Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Ann Rheum Dis. 2018 04; 77(4):563-570.
Score: 0.005
-
Regulation of human PRS isoform expression. Adv Exp Med Biol. 1998; 431:215-20.
Score: 0.005
-
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017 Jul; 76(7):1207-1218.
Score: 0.005
-
Overexpression of the normal phosphoribosylpyrophosphate synthetase 1 isoform underlies catalytic superactivity of human phosphoribosylpyrophosphate synthetase. J Biol Chem. 1996 Aug 16; 271(33):19894-9.
Score: 0.005
-
Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. Arthritis Rheumatol. 2016 08; 68(8):2035-43.
Score: 0.005
-
Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse. Int J Radiat Oncol Biol Phys. 2016 10 01; 96(2):372-378.
Score: 0.004
-
Determination of phosphoribosylpyrophosphate synthetase activity in human cells by a non-isotopic, one step method. Clin Chim Acta. 1996 Feb 09; 245(1):105-12.
Score: 0.004
-
The genetic and functional basis of purine nucleotide feedback-resistant phosphoribosylpyrophosphate synthetase superactivity. J Clin Invest. 1995 Nov; 96(5):2133-41.
Score: 0.004
-
Current Orthopaedic Surgeon Practices for Nonarthroplasty Treatment of Osteoarthritis of Adult Hip and Knee. J Surg Orthop Adv. 2015; 24(4):213-20.
Score: 0.004
-
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014 Dec; 20(8):427-32.
Score: 0.004
-
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Mol Cancer Ther. 2014 Aug; 13(8):1979-90.
Score: 0.004
-
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May; 165(4):504-9.
Score: 0.004
-
Flow-synchronized ventilation of preterm infants with respiratory distress syndrome. J Perinatol. 1994 Mar-Apr; 14(2):90-4.
Score: 0.004
-
A simplified method for the determination of phosphoribosylpyrophosphate synthetase activity in hemolysates. Clin Chim Acta. 1994 Jan 14; 224(1):55-63.
Score: 0.004
-
Point mutations in PRPS1, the gene encoding the PRPP synthetase (PRS) 1 isoform, underlie X-linked PRS superactivity associated with purine nucleotide inhibitor-resistance. Adv Exp Med Biol. 1994; 370:707-10.
Score: 0.004
-
Determination of the activity of recombinant human phosphoribosylpyrophosphate synthetase isoform 1 by a non-isotopic, one-step method. Adv Exp Med Biol. 1994; 370:821-4.
Score: 0.004
-
Human X-linked phosphoribosylpyrophosphate synthetase superactivity is associated with distinct point mutations in the PRPS1 gene. J Biol Chem. 1993 Dec 15; 268(35):26476-81.
Score: 0.004
-
A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1745-52.
Score: 0.004
-
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26; 15(5):R137.
Score: 0.004
-
A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leuk Res. 2013 Dec; 37(12):1622-7.
Score: 0.004
-
Overexpression, purification, and characterization of recombinant human 5-phosphoribosyl-1-pyrophosphate synthetase isozymes I and II. J Biol Chem. 1993 May 15; 268(14):10168-75.
Score: 0.004
-
Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Ann Neurol. 2012 May; 71(5):614-23.
Score: 0.003
-
Regulation of purine nucleotide synthesis in human B lymphoblasts with both hypoxanthine-guanine phosphoribosyltransferase deficiency and phosphoribosylpyrophosphate synthetase superactivity. J Biol Chem. 1992 Mar 05; 267(7):4317-21.
Score: 0.003
-
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb; 64(2):256-61.
Score: 0.003
-
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17; 306(7):711-20.
Score: 0.003
-
Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol. 2011 Jul; 38(7):1452-7.
Score: 0.003
-
Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol. 2011 Jul; 38(7):1458-61.
Score: 0.003
-
Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology? J Rheumatol. 2011 Jul; 38(7):1462-6.
Score: 0.003
-
Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol. 2011 Jul; 38(7):1467-70.
Score: 0.003
-
Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. Am J Hematol. 2011 Aug; 86(8):712-4.
Score: 0.003
-
Identification of distinct PRS1 mutations in two patients with X-linked phosphoribosylpyrophosphate synthetase superactivity. Adv Exp Med Biol. 1991; 309B:125-8.
Score: 0.003
-
Human phosphoribosylpyrophosphate synthetase (PRS) 2: an independent active, X chromosome-linked PRS isoform. Adv Exp Med Biol. 1991; 309B:129-32.
Score: 0.003
-
Multicenter crossover study of automated control of inspired oxygen in ventilated preterm infants. Pediatrics. 2011 Jan; 127(1):e76-83.
Score: 0.003
-
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1033-42.
Score: 0.003
-
Cloning of cDNAs for human phosphoribosylpyrophosphate synthetases 1 and 2 and X chromosome localization of PRPS1 and PRPS2 genes. Genomics. 1990 Nov; 8(3):555-61.
Score: 0.003
-
Registration of coronary venous anatomy to the site of the latest mechanical contraction. Acta Cardiol. 2010 Apr; 65(2):161-70.
Score: 0.003
-
Rheumatology. JAMA. 1989 May 19; 261(19):2887-8.
Score: 0.003
-
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb; 48(2):188-94.
Score: 0.003
-
PRPP and purine nucleotide metabolism in human lymphoblasts with both PRPP synthetase superactivity and HGPRT deficiency. Adv Exp Med Biol. 1989; 253B:13-20.
Score: 0.003
-
Neurodevelopmental impairment and deranged PRPP and purine nucleotide synthesis in inherited superactivity of PRPP synthetase. Adv Exp Med Biol. 1989; 253A:15-22.
Score: 0.003
-
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15; 59(11):1540-8.
Score: 0.003
-
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
Score: 0.003
-
Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness. Am J Med. 1988 Sep; 85(3):383-90.
Score: 0.003
-
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008 Sep; 58(9):2882-91.
Score: 0.003
-
The SPINK1 N34S variant is associated with acute pancreatitis. Eur J Gastroenterol Hepatol. 2008 Aug; 20(8):726-31.
Score: 0.003
-
Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout). Rheum Dis Clin North Am. 1988 Aug; 14(2):377-94.
Score: 0.003
-
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec; 32(12):1830-6.
Score: 0.003
-
Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia. J Mol Diagn. 2008 Jul; 10(4):338-45.
Score: 0.003
-
A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis. 2008 Jun; 67(6):888-91.
Score: 0.002
-
Regulation of purine synthesis de novo in human fibroblasts by purine nucleotides and phosphoribosylpyrophosphate. J Biol Chem. 1987 Oct 25; 262(30):14531-7.
Score: 0.002
-
Outcome evaluations in gout. J Rheumatol. 2007 Jun; 34(6):1381-5.
Score: 0.002
-
Mechanisms of accelerated purine nucleotide synthesis in human fibroblasts with superactive phosphoribosylpyrophosphate synthetases. J Biol Chem. 1987 Apr 25; 262(12):5596-602.
Score: 0.002
-
Phosphoribosylpyrophosphate synthetase superactivity. A study of five patients with catalytic defects in the enzyme. Arthritis Rheum. 1986 Jul; 29(7):880-8.
Score: 0.002
-
Superactivity of human phosphoribosyl pyrophosphate synthetase due to altered regulation by nucleotide inhibitors and inorganic phosphate. Biochim Biophys Acta. 1986 Jun 19; 882(2):168-76.
Score: 0.002
-
Magnetic resonance imaging in the quantitative assessment of gouty tophi. Int J Clin Pract. 2006 Apr; 60(4):408-14.
Score: 0.002
-
PRPP synthetase superactivity in lymphoblast lines. Adv Exp Med Biol. 1986; 195 Pt A:51-8.
Score: 0.002
-
Inherited phosphoribosylpyrophosphate synthetase superactivity due to aberrant inhibitor and activator responsiveness. Adv Exp Med Biol. 1986; 195 Pt A:59-66.
Score: 0.002
-
Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol. 2005 Dec; 32(12):2368-72.
Score: 0.002
-
Outcome measures for acute and chronic gout. J Rheumatol. 2005 Dec; 32(12):2452-5.
Score: 0.002
-
Selective expression of phosphoribosylpyrophosphate synthetase superactivity in human lymphoblast lines. J Clin Invest. 1985 Oct; 76(4):1657-64.
Score: 0.002
-
Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005 Sep; 11(9):680-7.
Score: 0.002
-
Immediate changes in lung compliance following natural surfactant administration in premature infants with respiratory distress syndrome: a controlled trial. J Perinatol. 2004 Oct; 24(10):626-30.
Score: 0.002
-
Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet. 2004 Sep 18-24; 364(9439):1054-61.
Score: 0.002
-
Human phosphoribosylpyrophosphate synthetase: radioimmunochemical quantitation in erythrocytes and fibroblasts. J Lab Clin Med. 1984 Jul; 104(1):96-109.
Score: 0.002
-
Diagnostic evaluation of phosphoribosylpyrophosphate synthetase activities in hemolysates. J Lab Clin Med. 1984 Jun; 103(6):932-43.
Score: 0.002
-
Human phosphoribosylpyrophosphate (PRPP) synthetase requirements for subunit aggregation. Adv Exp Med Biol. 1984; 165 Pt A:427-32.
Score: 0.002
-
Phosphoribosylpyrophosphate synthetase superactivity: detection, characterization of underlying defects, and treatment. Adv Exp Med Biol. 1984; 165 Pt A:91-96.
Score: 0.002
-
Radioimmunoassay studies of human phosphoribosylpyrophosphate synthetase. Adv Exp Med Biol. 1984; 165 Pt B:5-10.
Score: 0.002
-
Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003 Aug; 9(8):505-11.
Score: 0.002
-
Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman. Arthritis Rheum. 2003 Jul; 48(7):2036-41.
Score: 0.002
-
A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003 May; 9(3):176-8.
Score: 0.002
-
Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations. Gastroenterology. 2002 Oct; 123(4):1020-5.
Score: 0.002
-
Relationship of neonatal endotracheal tube size and airway resistance. Respir Care. 2002 Sep; 47(9):994-7.
Score: 0.002
-
Mutations of the serine protease inhibitor, Kazal type 1 gene, in patients with idiopathic chronic pancreatitis. Am J Gastroenterol. 2002 May; 97(5):1133-7.
Score: 0.002
-
Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate. J Lab Clin Med. 1982 Apr; 99(4):495-511.
Score: 0.002
-
The phosphogluconate pathway and synthesis of 5-phosphoribosyl-1-pyrophosphate in human fibroblasts. Biochim Biophys Acta. 1981 Nov 18; 678(1):51-7.
Score: 0.002
-
Regulation of 5-phosphoribosyl-1-pyrophosphate synthesis in human fibroblasts by the concentration of inorganic phosphate. Biochim Biophys Acta. 1981 Nov 18; 678(1):58-64.
Score: 0.002
-
Inhibition of phosphoribosylpyrophosphate synthesis in human fibroblasts by 6-methylthioinosinate. J Biol Chem. 1981 Feb 25; 256(4):1839-45.
Score: 0.002
-
Superactive phosphoribosylpyrophosphate synthetase with altered regulatory and catalytic properties. Adv Exp Med Biol. 1980; 122A:387-92.
Score: 0.001
-
Variant human phosphoribosylpyrophosphate synthetase altered in regulatory and catalytic functions. J Clin Invest. 1980 Jan; 65(1):109-20.
Score: 0.001
-
Simultaneous estimation of rates of pyrimidine and purine nucleotide synthesis de novo in cultured human cells. J Biol Chem. 1979 Dec 25; 254(24):12595-602.
Score: 0.001
-
Regional localization of the gene for human phosphoribosylpyrophosphate synthetase on the X chromosome. Science. 1979 Mar 09; 203(4384):1016-9.
Score: 0.001
-
Determinants of 5-phosphoribosyl-1-pyrophosphate (PRPP) synthesis in human fibroblasts. Adv Exp Med Biol. 1979; 122B:31-4.
Score: 0.001
-
Synthesis of phosphoribosylpyrophosphate in mammalian cells. Adv Enzymol Relat Areas Mol Biol. 1979; 49:281-306.
Score: 0.001
-
Methylmercaptopurine ribonucleoside toxicity in human fibroblasts: inhibition of phosphoribosylpyrophosphate synthetase as well as amidophosphoribosyltransferase. Adv Exp Med Biol. 1979; 122B:137-43.
Score: 0.001
-
Simultaneous determination of rates of purine and pyrimidine synthesis in cultured human lymphoblasts and fibroblasts. Adv Exp Med Biol. 1979; 122B:223-9.
Score: 0.001
-
Spontaneous minute ventilation predicts readiness for extubation in mechanically ventilated preterm infants. J Perinatol. 1998 Nov-Dec; 18(6 Pt 1):436-9.
Score: 0.001
-
Evidence for X-linkage of human phosphoribosylpyrophosphate synthetase. Proc Natl Acad Sci U S A. 1978 Jan; 75(1):482-5.
Score: 0.001
-
Uricosuric effects of niridazole. Clin Pharmacol Ther. 1977 Nov; 22(5 Pt 1):568-72.
Score: 0.001
-
Comparison of two methods of surfactant administration and the effect on dosing-associated hypoxemia. J Perinatol. 1997 Nov-Dec; 17(6):450-4.
Score: 0.001
-
Human erythrocyte phosphoribosylpyrophosphate synthetase. Subunit analysis and states of subunit association. J Biol Chem. 1977 Jun 10; 252(11):3911-8.
Score: 0.001
-
Human erythrocyte phosphoribosylpyrophosphate synthetase. Dependence of activity on state of subunit association. J Biol Chem. 1977 Jun 10; 252(11):3919-25.
Score: 0.001
-
Fibroblast phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in gout with purine overproduction. Adv Exp Med Biol. 1977; 76A:270-9.
Score: 0.001
-
Human phosphoribosylpyrophosphate synthetase: relation of activity and quaternary structure. Adv Exp Med Biol. 1977; 76A:71-9.
Score: 0.001
-
Diminished affinity for purine substrates as a basis for gout with mild deficiency of hypoxanthine-guanine phosphoribosyltransferase. Adv Exp Med Biol. 1977; 76A:319-25.
Score: 0.001
-
Effects of inosine on purine synthesis in normal and HGPRT-deficient human fibroblasts. Adv Exp Med Biol. 1977; 76A:370-5.
Score: 0.001
-
Hip involvement in ankylosing spondylitis. Arthritis Rheum. 1976 Jul-Aug; 19(4):683-92.
Score: 0.001
-
Regulation of purine nucleotide synthesis. Effects of inosine on normal and hypoxantine-guanine phosphoribosyltransferase-deficient fibroblasts. Biochim Biophys Acta. 1976 Jun 18; 435(2):132-44.
Score: 0.001
-
Ventilatory management casebook. Successful treatment of pulmonary interstitial emphysema with high-frequency oscillation after unsuccessful high-frequency jet ventilation. J Perinatol. 1996 May-Jun; 16(3 Pt 1):222-30.
Score: 0.001
-
Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction. J Clin Invest. 1976 Feb; 57(2):308-18.
Score: 0.001
-
Recent advances in the identification of enzyme abnormalities underlying excessive purine synthesis in man. Arthritis Rheum. 1975 Nov-Dec; 18(6 Suppl):687-94.
Score: 0.001
-
Effects of oxipurinol on pyrimidine nucleotide synthesis in human lymphoblasts. Arthritis Rheum. 1975 Nov-Dec; 18(6 Suppl):871-6.
Score: 0.001
-
Human phosphoribosylpyrophosphate synthetase. Comparison of purified normal and mutant enzymes. J Biol Chem. 1975 Sep 10; 250(17):6822-30.
Score: 0.001
-
Inhibition of human 5-phosphoribosyl-1-pyrophosphate synthetase by 4-amino-8-(beta-D-ribofuranosylamino)-pyrimido[5,4-d]pyrimidine-5'- monophosphate: evidence for interaction at the ADP allosteric site. Mol Pharmacol. 1995 Apr; 47(4):810-5.
Score: 0.001
-
Ventilatory management casebook. Bronchopulmonary dysplasias. Response to pressure support ventilation. J Perinatol. 1994 Nov-Dec; 14(6):495-7.
Score: 0.001
-
Genetic aspects of gout. Annu Rev Med. 1974; 25(0):15-28.
Score: 0.001
-
Human phosphoribosylpyrophosphate synthetase: increased enzyme specific activity in a family with gout and excessive purine synthesis. Proc Natl Acad Sci U S A. 1973 Oct; 70(10):2749-52.
Score: 0.001
-
Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity. Am J Med. 1973 Aug; 55(2):232-42.
Score: 0.001
-
Purine overproduction in man associated with increased phosphoribosylpyrophosphate synthetase activity. Science. 1973 Mar 16; 179(4078):1123-6.
Score: 0.001
-
Increased PP-ribose-P synthetase activity: a genetic abnormality leading to excessive purine production and gout. Adv Exp Med Biol. 1973; 41:307-15.
Score: 0.001
-
Ventilatory management casebook. Neonatal respiratory failure: response to volume ventilation. J Perinatol. 1993 Jan-Feb; 13(1):72-5.
Score: 0.001
-
Physical mapping of loci in the distal half of the short arm of the human X chromosome: implications for the spreading of X-chromosome inactivation. Somat Cell Mol Genet. 1992 Mar; 18(2):195-200.
Score: 0.001
-
Increased purine nucleotide degradation in the central nervous system (CNS) in PRPP synthetase superactivity. Adv Exp Med Biol. 1989; 253A:9-13.
Score: 0.001
-
Structural analysis of polymers of sickle cell hemoglobin. III. Fibers within fascicles. J Mol Biol. 1988 Jan 20; 199(2):383-8.
Score: 0.001
-
Reaction of antibody to normal human hypoxanthine phosphoribosyltransferase with products of mutant genes. Arch Biochem Biophys. 1976 Dec; 177(2):415-26.
Score: 0.000
-
Evaluation of the role of 5-phosphoribosyl-alpha-1-pyrophosphate synthetase in congenital hyperuricemia and gout: a simple isotopic assay and an activity stain for the enzyme. Biochem Med. 1974 Jul; 10(3):266-75.
Score: 0.000
-
Purine metabolism in normal and thioguanine-resistant neuroblastoma. Proc Natl Acad Sci U S A. 1973 Dec; 70(12):3880-3.
Score: 0.000
-
Purine nucleotide synthesis in lymphoblasts cultured from normal subjects and a patient with Lesch-Nyhan syndrome. Biochem Genet. 1973 Jul; 9(3):261-74.
Score: 0.000
-
Effects of nicotinic acid on human fibroblast purine biosynthesis. Biochim Biophys Acta. 1972 May 10; 269(2):179-83.
Score: 0.000